Changing predictors of mortality over time from cART start: Implications for care

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 3, 2011, Pages 269-273

  Hoffmann, Christopher J ^a,b   Fielding, Katherine L ^c   Johnston, Victoria ^c   Charalambous, Salome ^b   Innes, Craig ^b   Moore, Richard D ^a   Chaisson, Richard E ^a   Grant, Alison D ^c   Churchyard, Gavin J ^b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AURUM INSTITUTE   (South Africa)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Africa; antiretroviral therapy; HIV; mortality; proportional hazards; resource limited setting

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; HEMOGLOBIN; HUMAN IMMUNODEFICIENCY VIRUS RNA; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ANEMIA; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; CLINICAL STUDY; COHORT ANALYSIS; COMBINATION ANTIRETROVIRAL THERAPY; COUGHING; FEMALE; FEVER; FOLLOW UP; GENDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NIGHT SWEAT; PREDICTOR VARIABLE; PRIORITY JOURNAL; SPUTUM; TUBERCULOSIS; WEIGHT REDUCTION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SOUTH AFRICA; TIME FACTORS;

EID: 80054921123     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31823219d1     Document Type: Article

References (51)

1. Herbst AJ, Cooke GS, Barnighausen T, et al. Adult mortality and antiretroviral treatment roll-out in rural KwaZulu-Natal, South Africa. Bull World Health Organ. 2009;87:754-762.
2. Mashego M, Johnson D, Frohlich J, et al. High AIDS-related mortality among young women in rural KwaZulu-Natal. S Afr Med J. 2007;97: 587-592. (Pubitemid 47412018)
3. Kahn K, Garenne ML, Collinson MA, et al. Mortality trends in a new South Africa: hard to make a fresh start. Scand J Public Health Suppl. 2007;69:26-34. (Pubitemid 47241577)
4. Lawn SD, Little F, Bekker LG, et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS. 2009;23:335-342.
5. Jahn A, Floyd S, Crampin AC, et al. Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet. 2008;371:1603-1611. (Pubitemid 351626844)
6. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003; 362:22-29. (Pubitemid 36835816)
7. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-824.
8. Rosenthal E, Pialoux G, Bernard N, et al. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat. 2007;14:183-188.
9. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355: 2283-2296. (Pubitemid 44837777)
10. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349: 1993-2003.
11. Selik RM, Byers RH, Jr., Dworkin MS. Trends in diseases reported on U. S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr. 2002;29:378-387. (Pubitemid 34288892)
12. Mocroft A, Sterne JA, Egger M, et al. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis. 2009;48:1138-1151.
13. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol. 2005;34:121-130. (Pubitemid 40347381)
14. Hoffmann CJ, Seaberg EC, Young S, et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS. 2009;23: 1881-1889.
15. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D: A:D) study. J Infect Dis. 2010;201:318-330.
16. Smith C. Factors associated with specific causes of death amongst HIVpositive individuals in the D: A:D Study. AIDS. 2010;24:1537-1548.
17. Palella FJ, Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43: 27-34. (Pubitemid 44306484)
18. Martinson NA, Karstaedt A, Venter WD, et al. Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. AIDS. 2007;21:2043-2050. (Pubitemid 47462153)
19. Mzileni MO, Longo-Mbenza B, Chephe TJ. Mortality and causes of death in HIV-positive patients receiving antiretroviral therapy at Tshepang Clinic in Doctor George Mukhari Hospital. Pol Arch Med Wewn. 2008;118:548-554.
20. Garcia-Jardon M, Bhat VG, Blanco-Blanco E, et al. Postmortem findings in HIV/AIDS patients in a tertiary care hospital in rural South Africa. Trop Doct. 2010;40:81-84.
21. Moh R, Danel C, Messou E, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS. 2007;21:2483-2491. (Pubitemid 350145180)
22. Zachariah R, Fitzgerald M, Massaquoi M, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS. 2006;20:2355-2360. (Pubitemid 44789538)
23. Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006;20:1181-1189. (Pubitemid 43786107)
24. Johannessen A, Naman E, Ngowi BJ, et al. Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis. 2008;8:52.
25. Lawn SD, Myer L, Orrell C, et al. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS. 2005;19:2141-2148. (Pubitemid 41669003)
26. Zachariah R, Harries K, Moses M, et al. Very early mortality in patients starting antiretroviral treatment at primary health centres in rural Malawi. Trop Med Int Health. 2009;14:713-721.
27. Boulle A, Van CG, Hilderbrand K, et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS. 2010;24:563-572.
28. Jerene D, Endale A, Hailu Y, et al. Predictors of early death in a cohort of Ethiopian patients treated with HAART. BMC Infect Dis. 2006;6:136.
29. Chi BH, Giganti M, Mulenga PL, et al. CD4+ response and subsequent risk of death among patients on antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr. 2009;52:125-131.
30. Castelnuovo B, Manabe YC, Kiragga A, et al. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis. 2009;49:965-972.
31. May M, Boulle A, Phiri S, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet. 2010;376:449-457.
32. Mills EJ, Bakanda C, Birungi J, et al. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. AIDS. 2011;25:851-855.
33. Marazzi MC, Liotta G, Germano P, et al. Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings. AIDS Res Hum Retroviruses. 2008;24:555-560. (Pubitemid 351571039)
34. Steele KT, Steenhoff AP, Newcomb CW, et al. Early mortality and AIDS progression despite high initial antiretroviral therapy adherence and virologic suppression in botswana. PLoS One. 2011;6:e20010.
35. Hoffmann CJ, Fielding KL, Charalambous S, et al. Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa. AIDS. 2010;24:1709-1716.
36. Brinkhof MW, Boulle A, Weigel R, et al. Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality. PLoS Med. 2009;6:e1000066.
37. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296:782-793. (Pubitemid 44223102)
38. Geng EH, Emenyonu N, Bwana MB, et al. Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA. 2008;300:506-507.
39. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-824.
40. Bisson GP, Gaolathe T, Gross R, et al. Overestimates of survival after HAART: implications for global scale-up efforts. PLoS One. 2008;3:e1725.
41. Fox MP, Brennan A, Maskew M, et al. Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. Trop Med Int Health. 2010;15:405-413.
42. Anderson B, Phillips H. Adult mortality (age 16-64) based on death notification data in South Africa: 1997-2004. Reportno: 03-09-05, 1-180, 2006. Pretoria, South Africa; Statistics South Africa.
43. Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006;20:1181-1189. (Pubitemid 43786107)
44. Fairall LR, Bachmann MO, Louwagie GM, et al. Effectiveness of antiretroviral treatment in a South African program: a cohort study. Arch Intern Med. 2008;168:86-93.
45. Fielding KL, Charalambous S, Stenson AL, et al. Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study. BMC Infect Dis. 2008;8:93.
46. Brown ER, Otieno P, Mbori-Ngacha DA, et al. Comparison of CD4 cell count, viral load, and other markers for the prediction of mortality among HIV-1-infected Kenyan pregnant women. J Infect Dis. 2009;199:1292-1300.
47. Fox MP, Brennan A, Maskew M, et al. Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. Trop Med Int Health. 2010;15:405-413.
48. MacPherson P, Moshabela M, Martinson N, et al. Mortality and loss to follow-up among HAART initiators in rural South Africa. Trans R Soc Trop Med Hyg. 2009;103:588-593.
49. Hanrahan CF, Golub JE, Mohapi L, et al. Body mass index and risk of tuberculosis and death. AIDS. 2010;24:1501-1508.
50. French AL, Gawel SH, Hershow R, et al. Trends in mortality and causes of death among women with HIV in the United States: a 10-year study. J Acquir Immune Defic Syndr. 2009;51:399-406.
51. Hooshyar D, Hanson DL, Wolfe M, et al. Trends in perimortal conditions and mortality rates among HIV-infected patients. AIDS. 2007;21: 2093-2100. (Pubitemid 47462159)